LYRA (Lyra Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on LYRA (Lyra Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

LYRA

Lyra Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 12, 2025
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Oct 6, 2025
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Aug 12, 2025
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 12, 2025
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Jun 27, 2025
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
Jun 12, 2025
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
Jun 5, 2025
Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win
Jun 2, 2025
Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints
Jun 2, 2025
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
May 7, 2025
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
May 6, 2025
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 6, 2025
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Mar 13, 2025
Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know
Jan 9, 2025

Reviews